Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Payables: 2009-2025

Historic Payables for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to $556,000.

  • Gyre Therapeutics' Payables rose 83.50% to $556,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $857,000, marking a year-over-year decrease of 31.93%. This contributed to the annual value of $108,000 for FY2024, which is 69.58% down from last year.
  • Per Gyre Therapeutics' latest filing, its Payables stood at $556,000 for Q3 2025, which was up 683.10% from $71,000 recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Payables ranged from a high of $7.7 million in Q4 2022 and a low of $5,000 during Q2 2023.
  • Its 3-year average for Payables is $208,636, with a median of $158,000 in 2023.
  • Per our database at Business Quant, Gyre Therapeutics' Payables crashed by 99.66% in 2023 and then spiked by 5,320.00% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Payables (Quarterly) stood at $6.4 million in 2021, then increased by 19.64% to $7.7 million in 2022, then slumped by 95.38% to $355,000 in 2023, then slumped by 69.58% to $108,000 in 2024, then spiked by 83.50% to $556,000 in 2025.
  • Its Payables stands at $556,000 for Q3 2025, versus $71,000 for Q2 2025 and $122,000 for Q1 2025.